OptimizeRx OPRX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 70%+14.1pp | 67.3%+27.0pp | 65.3%+30.1pp | 64.4%+33.3pp | 55.9%+8.1pp | |
| Operating margin | 13.2%— | 10.7%— | —— | —— | —— | |
| Net margin | 6.4%+26.4pp | 4.7%+41.4pp | 0%+47.5pp | -9.4%+29.6pp | -20.1%+10.8pp | |
| EBITDA margin | 17.2%— | 14.7%— | —— | —— | —— | |
| Free cash flow margin | 13.4%+4.8pp | 17%+8.3pp | 10.7%+14.0pp | 9.9%— | 8.5%— | |
| Returns | ||||||
| Return on equity | 5.6%+18.5pp | 4.2%+20.7pp | 0%+21.0pp | -8.2%+6.9pp | -12.9%+1.8pp | |
| Return on assets | 4.1%+13.0pp | 2.9%+14.3pp | 0%+16.7pp | -5.8%+6.4pp | -9%+2.8pp | |
| Return on invested capital | 7.6%— | 6.4%— | —— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.6×+0.2× | 0.6×+0.3× | 0.7×+0.3× | 0.6×+0.3× | 0.4×+0.1× | |
| Liquidity | ||||||
| Current ratio | 5.4×+2.6× | 3×+0.2× | 3×-0.2× | 2.6×-0.5× | 2.8×-0.1× | |
| Quick ratio | 5.4×+2.6× | 3×+0.2× | 3×-0.2× | 2.6×-0.5× | 2.8×-0.1× | |
| Cash ratio | 1.9×+1.0× | 1.1×+0.4× | 1.1×-0.1× | 0.8×-0.2× | 0.9×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×-0.1× | 0.2×-0.1× | 0.2×-0.1× | 0.2×-0.1× | 0.3×0.0× | |
| Debt-to-assets | 0.1×-0.1× | 0.1×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Net debt / EBITDA | 0.2×— | 0.2×— | —— | —— | —— | |
| Interest coverage | 2.8×— | 2.2×— | —— | —— | —— | |
| Per Share | ||||||
| Book value per share | $6.91+9.7% | $6.75+5.6% | $6.28+0.6% | $6.27-5.4% | $6.29-6.7% | |
| Valuation | ||||||
| Market capitalization | $107.34M-54.1% | $228.53M+155% | $380.58M+169% | $238.59M+30.6% | $160.13M-27.4% | |
| Enterprise value | $110.88M-55.0% | $231.27M+112% | $389.67M+142% | $250.98M+23.1% | $176.35M-26.9% | |
| Price / earnings | 15.7×— | 44.5×— | 11,193.6×— | —— | —— | |
| Price / sales | 1×-1.2× | 2.1×+0.5× | 3.5×+0.7× | 2.3×-1.7× | 2.1×-1.7× | |
| Price / book | 0.8×-1.1× | 1.8×+1.0× | 3.1×+1.9× | 2×+0.5× | 1.4×-0.4× | |
| EV / EBITDA | 6×— | 14.4×— | —— | —— | —— | |
| EV / sales | 1×-1.3× | 2.1×+0.1× | 3.6×+0.4× | 2.4×-2.0× | 2.3×-1.8× | |
| Free cash flow yield | 13.4%+8.9pp | 8.2%+2.8pp | 3.1%+4.3pp | 4.3%— | 4.1%— | |
| Earnings yield | 6.4%+10.6pp | 2.2%+24.7pp | 0%+17.1pp | -4.1%+5.7pp | -9.6%-1.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are OptimizeRx's profit margins?
- OptimizeRx (OPRX) runs a 70.0% gross margin and a 13.2% operating margin, with a 6.4% net margin.
- Where do OptimizeRx's ratios come from?
- Every ratio is computed from OptimizeRx's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
